Italia markets open in 35 minutes
  • Dow Jones

    35.677,02
    +73,92 (+0,21%)
     
  • Nasdaq

    15.090,20
    -125,50 (-0,82%)
     
  • Nikkei 225

    28.600,41
    -204,44 (-0,71%)
     
  • EUR/USD

    1,1658
    +0,0012 (+0,10%)
     
  • BTC-EUR

    53.108,68
    +408,62 (+0,78%)
     
  • CMC Crypto 200

    1.453,34
    -49,70 (-3,31%)
     
  • HANG SENG

    26.142,09
    +15,16 (+0,06%)
     
  • S&P 500

    4.544,90
    -4,88 (-0,11%)
     

Silence Therapeutics to Participate in September Investor Conferences

·2 minuto per la lettura

Silence Therapeutics to Participate in September Investor Conferences

25 August 2021

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that Company management will present at two virtual investor conferences in September, details of which can be found below:

Morgan Stanley 19th Annual Global Healthcare Conference

Format: Fireside Chat

Date: Friday, September 10th

Time: 11:45am EDT / 4:45pm BST

H.C. Wainwright 23rd Annual Global Investment Conference

Format: Company Presentation

Date: Monday, September 13th

Time: On-demand starting at 7:00am EDT / 12:00pm BST

Webcasts of the fireside chat and presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcasts will be available on the Company’s website following the conference.

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com



Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.


Il nostro obiettivo è creare un luogo sicuro e coinvolgente in cui gli utenti possano entrare in contatto per condividere interessi e passioni. Per migliorare l’esperienza della nostra community, sospendiamo temporaneamente i commenti sugli articoli